DHAIFALAH, I., Ladislav DUŠEK and J. ŠANTAVÝ. Nová metoda screeningu Downova syndromu v I. trimestru: One-Stop-Clinic for Assessment of Risk (OSCAR) (New method of first trimester screening for Down’s Syndrome: One-Stop-Clinic for Assessment of Risk (OSCAR)). Česká gynekologie. 2011, vol. 76, No 4, p. 292-306. ISSN 1210-7832.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Nová metoda screeningu Downova syndromu v I. trimestru: One-Stop-Clinic for Assessment of Risk (OSCAR)
Name (in English) New method of first trimester screening for Down’s Syndrome: One-Stop-Clinic for Assessment of Risk (OSCAR)
Authors DHAIFALAH, I. (203 Czech Republic, guarantor), Ladislav DUŠEK (203 Czech Republic, belonging to the institution) and J. ŠANTAVÝ (203 Czech Republic).
Edition Česká gynekologie, 2011, 1210-7832.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30214 Obstetrics and gynaecology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/11:00054109
Organization unit Faculty of Medicine
Keywords (in Czech) screening Downova syndromu v I. trimestru; One-Stop-Clinic; OSCAR; nuchální translucence; nosní kůstka
Keywords in English implementation of first trimester screening; one stop clinic (OSCAR); nuchal translucency; nasal bone
Tags Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 28/11/2011 16:10.
Abstract
Představení a zavedení nové metody screeningu Downova syndromu v I. trimestru pomocí měření nuchální translucence, přítomnosti nosní kůstky, PAPP-A (maternal serum pregnancy associated plasma protein-A) a free beta-human chorionic gonadotropin, v tzv. One-Stop-Clinic for Assessment of Risk (OSCAR) v České republice. Dokumentovat efektivitu metody a zavést ji jako screeningovou metodu volby. Upravit a změnit současný systém screeningu. Prospektivní studie 5010 jednočetných těhotenství matek, které byly vyšetřeny na našem pracovišti prenatálního screeningu chromozomálních a vrozených vývojových vad mezi 11. a 13.+6 týdnem gestace mezi lednem 2005 a prosincem 2007. Těhotenství byla sledována do porodu a výsledek těhotenství je znám. Screeningové vyšetření se rozhodlo podstoupit 100 % žen, invazivní vyšetření 95 % žen s pozitivním výsledkem screeningu. Všechny předpokládané trizomie 21 byly detekovány, spolu s dalšími chromozomálními aneuploidemi s falešnou pozitivitou 4,4 %. Studie demonstrovala proveditelnost a účinnost metody OSCAR ve screeningu chromozomálních aneuploidií ve fakultní nemocnici. Zavedení vyšetřování nosní kůstky snížilo míru falešné pozitivity a zvýšilo senzitivitu. Ženy, které screening podstoupily, již neabsolvovaly biochemický screning II. trimestru (triple test).
Abstract (in English)
Implementation and introducing of first trimester screening using nuchal translucency (NT), nasal bone (NB), maternal serum pregnancy associated plasma protein-A and free beta-human chorionic gonadotropin (PAPP-A and fbeta-hCG) as a new method of screening for Down’s Syndrome in a One-Stop-Clinic for Assessment of Risk for chromosomal abnormalities in the Czech Republic. To prove its effectiveness and make it part of our daily practice. Modify and/or withdraw the existing current practice. Prospective study of 5010 singleton pregnancies who attended our clinic for prenatal screening for chromosomal and congenital abnormalities between 11-13+6 weeks gestation from January 2005 to December 2007. Pregnancies were followed up to ascertain live birth of Down syndrome babies. The uptake was 100% for screening and around 95% for invasive testing in the screen positive group. All expected trisomies 21 were detected along with many other aneuploidies for false positive rate of 4.4%. The study demonstrated the feasibility and efficacy of introducing OSCAR for chromosomal abnormalities in a University Hospital setting. The introduction of an examination of nasal bone reduced our false positive results and increased our sensitivity. Women who participated in our screening strategy were no longer advised to undergo the triple test.
PrintDisplayed: 29/5/2024 16:41